Drugs / NNC0519-0130 B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06642571 | Oct 2024 → May 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0519-0130 B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06642571 ↗ |
| Route | Subcutaneous | “NNC0519-0130 B will be administered subcutaneously.” NCT06642571 ↗ |